Compare AbCellera Biologics Inc (ABCL) vs Jabil Inc (JBL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

JBL trades at $338.22, down 0.9% today, with technical indicators showing a bearish trend near support at $333. The stock has demonstrated strong earnings momentum, beating estimates for three consecutive quarters, and benefits from AI infrastructure demand driving revenue growth. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target suggesting significant upside potential.

The outlook remains positive due to AI-driven growth and margin expansion, though high valuation multiples and competitive pressures present risks. Recent manufacturing expansion in India and hyperscaler customer wins support long-term growth, but investors should monitor execution against elevated expectations.